Control of inflammation, cytokine expression, and germinal center formation by BCL-6

Science

Volumn 276, Issue 5312, 1997, Pages 589-592

  Dent, Alexander L ^a   Shaffer, Arthur L ^a   Yu, Xin ^a   Allman, David ^a   Staudt, Louis M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; TRANSCRIPTION FACTOR;

ANIMAL CELL; ARTICLE; BINDING SITE; GENE DISRUPTION; HELPER CELL; LARGE CELL LYMPHOMA; MOLECULAR RECOGNITION; MOUSE; MYOCARDITIS; NONHUMAN; PRIORITY JOURNAL; REPRESSOR GENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION;

ANIMALS; B-LYMPHOCYTES; CELLS, CULTURED; CYTOKINES; DNA-BINDING PROTEINS; FICOLL; GERMINAL CENTER; HEMOCYANIN; IMMUNOGLOBULINS; INFLAMMATION; INTERFERON TYPE II; INTERLEUKIN-4; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MICE; MYOCARDITIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-6; RECEPTORS, IGE; SIGNAL TRANSDUCTION; SPLEEN; STAT6 TRANSCRIPTION FACTOR; T-LYMPHOCYTES; TH2 CELLS; TRANS-ACTIVATORS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC; TRINITROBENZENES; VASCULITIS;

EID: 0030901289     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.276.5312.589     Document Type: Article

References (51)

1. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
2. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
3. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
4. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
5. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
6. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
7. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
8. B. H. Ye et al., Science 262, 747 (1993); A. Migliazza et al., Proc. Natl. Acad. Sci. U.S.A. 92, 12520 (1995); T. Miki, N. Kawamata, S. Hirosawa, N. Aoki, Blood 83, 26 (1994); J. P. Kerckaert et al., Nature Genet. 5, 66 (1993); B. W. Baron et al., Proc. Natl. Acad. Sci. U.S.A. 90, 5262 (1993); F. LoCoco et al., Blood 83, 1757 (1994); T. Otsuki et al., ibid. 85, 2877 (1995); C. Bastard et al., ibid. 83, 2423 (1994).
9. T. Onizuka et al., Blood 86, 28 (1995).
10. L. Flenghi et al., Am. J. Pathol. 147, 405 (1995).
11. G. Cattoretti et al., Blood 86, 45 (1995).
12. D. Allman et al., ibid. 87, 5257 (1996).
13. V. L. Seyfert, D. Allman, Y. He, L. M. Staudt, Oncogene 12, 2331 (1996).
14. P. Dhordain et al., ibid. 11, 2689 (1995); C. Deweindt et al., Cell Growth Differ. 6, 1495 (1995).
15. P. Dhordain et al., ibid. 11, 2689 (1995); C. Deweindt et al., Cell Growth Differ. 6, 1495 (1995).
16. C.-C. Chang, B. H. Ye, R. S. K. Chaganti, R. Dalla-Favera, Proc. Natl. Acad. Sci. U.S.A. 93, 6947 (1996).
17. B. H. Koller and O. Smithies, ibid. 86, 8932 (1989).
18. -/- mice used in these experiments resulted from intercrosses between the 129 strain from which the ES cells were derived and strain C57B1/6.
19. Mice were immunized intraperitoneally with 100 μg of TNP-KLH in complete Freund's adjuvant (CFA). After 12 days, splenocytes were lysed and immunoprecipitated with the indicated antibodies. Immunoprecipitates were electrophoresed through a 7.5% SDS-polyacrylamide gel electrophoresis gel, transferred to nitrocellulose, incubated, and developed with a rabbit antibody to BCL-6 (5), with the use of the ECL system (Amersham).
20. Bone marrow cells, splenocytes, and thymocytes were analyzed by flow cytometry for the following surface proteins: CD4, CD8, CD45R (B220), IgM, CD3, CD24 (HSA), CD43, CD11b (Mac1), Gr-1, CD90 (Thy-1), CD5, IgD, TCR-αβ, CD25, CD23, CD38, CD80 (B7.1), CD86 (B7.2), MHC class II (IA), CD11a (LFA-1), CD19, CD18, CD40 ligand, CTLA-4, and CD-69. No differences between BCL-6 mutant mice and wild-type littermate control mice were observed.
21. Mice 5 to 6 weeks old were immunized intraperitoneally with 100 μg of TNP-KLH in CFA. After 12 days, serum was collected for anti-TNP titers, and spleens were processed for immunohistochemistry by being embedded in OCT compound (Tissue-Tek) and frozen. Splenic cryosections were stained with PNA-horseradish peroxidase, biotin-anti-mouse IgD, and streptavidin-alkaline phosphatase according to standard procedures (15). For T cell-independent immunization, mice were injected intraperitoneally with 25 μg of TNP-conjugated Ficoll suspended in phosphate-buffered saline. Serum was collected for anti-TNP titers after 7 days. Anti-TNP titers were assayed from sera by ELISA on TNP-ovalbumin-coated plates with the use of alkaline phosphatase-conjugated, goat anti-mouse Ig antibodies specific for various Ig isotypes (Southern Biotech).
22. I. C. M. MacLennan, Annu. Rev. Immunol. 12, 117 (1994).
23. J. Jacob and G. Kelsoe, J. Exp. Med. 176, 679 (1992).
24. A. Dent, unpublished observations.
25. 6 per milliliter on anti-CD3 coated plates for 24 hours before collection of supernatants. ELISA antibodies and standards were obtained from Pharmingen (IFN-γ and IL-4), A. Sher (IL-5), and R&D Systems (IL-13). To prepare lung and heart inflammatory cells, tissues were minced, ground between glass slides, and filtered through a 70-μm nylon mesh.
26. T. R. Mosmann, H. Cherwinski, M. W. Bond, M. A. Giedlin, R. L. Coffman, J. Immunol. 136, 2348 (1986).
27. R. A. Seder, Annu. Rev. Immunol. 12, 635 (1994); A. K. Abbas, K. M. Murphy, A. Sher, Nature 383, 787 (1996).
28. R. A. Seder, Annu. Rev. Immunol. 12, 635 (1994); A. K. Abbas, K. M. Murphy, A. Sher, Nature 383, 787 (1996).
29. K. Takeda et al., Nature 380, 627 (1996); K. Shimoda et al., ibid., p. 630; M. H. Kaplan, U. Schindler, S. T. Smiley, M. J. Grusby, Immunity 4, 313 (1996).
30. K. Takeda et al., Nature 380, 627 (1996); K. Shimoda et al., ibid., p. 630; M. H. Kaplan, U. Schindler, S. T. Smiley, M. J. Grusby, Immunity 4, 313 (1996).
31. K. Takeda et al., Nature 380, 627 (1996); K. Shimoda et al., ibid., p. 630; M. H. Kaplan, U. Schindler, S. T. Smiley, M. J. Grusby, Immunity 4, 313 (1996).
32. C. Schindler and J. E. J. Darnell, Annu. Rev. Biochem. 64, 621 (1995).
33. N. Kawamata et al., Biochem. Biophys. Res. Commun. 204, 366 (1994); B. W. Baron et al., Genes Chromosomes Cancer 13, 221 (1995).
34. N. Kawamata et al., Biochem. Biophys. Res. Commun. 204, 366 (1994); B. W. Baron et al., Genes Chromosomes Cancer 13, 221 (1995).
35. 3-4GAA.
36. Etectrophoretic mobility-shift assay (EMSA) DNA binding reactions were performed essentially as described (6). The CD23b DMA probe sequence is 5′-GATCAGGGTGAATTTCTAAGAAAGGGACTGGTGT-3′. BCL-6 protein and the luciferase control protein were generated with in vitro translation as described (6). Nuclear extracts were prepared essentially as described (35). For antibody supershift analysis, 3 μg of antibody [anti-BCL-6 (N3) or anti-State (S20); Santa Cruz Biotechnology] or preimmune rabbit serum was used.
37. I. Kohler and E. P. Rieber, Eur. J. Immunol. 23, 3066 (1993).
38. J. Hou et al., Science 265 (1994); H. Kotanides and N. C. Reich, ibid. 262, 1265 (1993); C. Schindler, H. Kashleva, A. Pernis, R. Pine, P. Rothman, EMBO J. 13, 1350 (1994).
39. J. Hou et al., Science 265 (1994); H. Kotanides and N. C. Reich, ibid. 262, 1265 (1993); C. Schindler, H. Kashleva, A. Pernis, R. Pine, P. Rothman, EMBO J. 13, 1350 (1994).
40. J. Hou et al., Science 265 (1994); H. Kotanides and N. C. Reich, ibid. 262, 1265 (1993); C. Schindler, H. Kashleva, A. Pernis, R. Pine, P. Rothman, EMBO J. 13, 1350 (1994).
41. A CD23b luciferase reporter construct was prepared by tandem ligation of three human CD23b BCL-6/Stat6 sites (24) immediately 5′ to a minimal TK promoter (base pairs -81 to +52) in pGL2basic (Promega). NIH 3T3 cells were transfected by the calcium phosphate transfection method using 2 μg of β-galactosidase (β-Gal) expression vector (pSV2Bgal), 5 μg of CD23b reporter plasmid, 10 μg of Stat6 expression plasmid (in the vector pCEV27) or empty pCEV27 vector, and 10 μg of BCL-6 expression vector [pCGN-BCL-6 (6)] or empty pCGN vector control. The day after transfection, cells were incubated for 16 hours in serum-free medium and then treated with 500 U/ml (0.25 ng/ml) of mouse IL-4 for 6 hours. Cell extracts were prepared and analyzed with the Luciferase Assay System (Promega). Luciferase activity was normalized on the basis of β-Gal activity in each extract.
42. 6 WI-L2-NS cells were transfected with 6 μg of marker expression vector for mouse intercellular adhesion molecule-1 (ICAM) (pmICAM) and 30 μg of expression vector for BCL-6 [pCGN BCL-6 (6)] or empty vector (pCGN) using a BTX electroporator set at 260 V, 950 mF, and 720 ohms. After overnight culture, the transfected cells were stimulated with recombinant human IL-4 (10 ng/ml; Genzyme) for 16 hours and subsequently stained for flow cytometry with mouse anti-human CD23-PE (M-L233, Pharmingen) and hamster anti-mouse CD54/ICAM (3E2, Pharmingen).
43. V. Pascual et al., J. Exp. Med. 180, 329 (1994).
44. M. Matsumoto et al., Science 271, 1289 (1996); M. Pasparakis, L. Alexopoulou, V. Episkopou, G. Kollias, J. Exp. Med. 184, 1397 (1996).
45. M. Matsumoto et al., Science 271, 1289 (1996); M. Pasparakis, L. Alexopoulou, V. Episkopou, G. Kollias, J. Exp. Med. 184, 1397 (1996).
46. -/- and wild-type lymphocytes were comparable.
47. -/- mice (n = 5) had, on average, 3.1 μg/ml of serum IgE after immunization with TNP-KLH in CFA, whereas wild-type littermates (n = 6) had 0.36 μg/ml of serum IgE.
48. M. Kopf et al., Nature 362, 245 (1993).
49. V. L. Tybulewicz, C. E. Crawford, P. K. Jackson, R. T. Bronson, R. C. Mulligan, Cell 65, 1153 (1991).
50. E. Schrieber, P. Mattias, M. M. Muller, W. Schaffner, Nucleic Acids Res. 17, 6419 (1989).
51. -/- mice; J. Inman for TNP-Ficoll; W. LaRochelle for the State expression vector; P. Caspar and A. Sher for help with the anti-IL-5 ELISA and helpful discussions; B. Paul for recombinant mouse IL-4 and helpful discussions; K. Kelly for the pmICAM expression plasmid; and T. Waldmann, R. Germain, R. Hodes, and H. Morse for helpful discussions. Mice were maintained according to the NIH Office of Animal Care and Use guidelines.